Trials / Completed
CompletedNCT01109017
Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency
A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Long-term Safety and Efficacy of Norditropin® Formulation in Patients With AGHD
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 387 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Japan. The aim of this observational study is to collect information about the safety and efficacy of Norditropin® long-term treatment of growth hormone deficiency in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropin | Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5. |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2010-04-22
- Last updated
- 2015-01-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01109017. Inclusion in this directory is not an endorsement.